Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM

Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL

Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL

A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma

ASCO 2022: Head and neck cancer highlights

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

ASCO 2022: Breast cancer highlights

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone